Screener
Aquestive Therapeutics, Inc. AQST EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Aquestive Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s EBITDA margin?
- Aquestive Therapeutics, Inc. (AQST) reported EBITDA margin of -96.6% in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Aquestive Therapeutics, Inc.'s EBITDA margin increased by 18.1% year-over-year, from -117.9% to -96.6%.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s EBITDA margin has grown at a 13.0% compound annual growth rate (CAGR), from -86% to -158.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Aquestive Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude